|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intracellular and extracellular TGF-β signaling in cancer: some recent topics显示文摘 | Kohei Miyazono Yoko Katsuno Daizo Koinuma Shogo Ehata Masato Morikawa | 2018 | Frontiers of Medicine2018，12，4： | 16 |
| 2 | Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis显示文摘Bone is one of the preferred sites for the metastasis of malignant tumours,such as breast cancer,lung cancer and malignant melanoma.Tumour cells colonizing bone have the capacity to induce the expression of receptor activator of nuclear factor-κB ligand(RANKL),which promotes osteoclast differentiation and activation.Tumour-induced osteoclastic bone resorption leads to a vicious cycle between tumours and bone cells that fuels osteolytic tumour growth,causing bone pain and hypercalcaemia.Furthermore,RANKL contributes to bone metastasis by acting as a chemoattractant to bone for tumour cells that express its receptor,RANK.Thus inhibition of the RANKL–RANK pathway is a promising treatment for bone metastasis,and a human monoclonal anti-RANKL antibody,denosumab,has been used in the clinic.However,orally available drugs targeting RANKL must be developed to increase the therapeutic benefits to patients.Here we report the efficacy of the small-molecule RANKL inhibitor AS2676293 in treating bone metastasis using mouse models.Oral administration of AS2676293 markedly inhibited bone metastasis of human breast cancer cells MDA-MB-231-5a-D-Luc2 as well as tumour-induced osteolysis.AS2676293 suppressed RANKLmediated tumour migration in the transwell assay and inhibited bone metastasis of the murine cell line B16F10,which is known not to trigger osteoclast activation.Based on the results from this study,RANKL inhibition with a small-molecule compound constitutes a promising therapeutic strategy for treating bone metastasis by inhibiting both osteoclastic bone resorption and tumour migration to bone. | Yuta Nakai Kazuo Okamoto Asuka Terashima Shogo Ehata Jun Nishida Takeshi Imamura Takashi Ono Hiroshi Takayanagi | 2019 | Bone Research2019，7，1： | 8 |
| 3 | Mutation in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis显示文摘 | OMATA M EHATA T YOKOSUKA O | 1991 | N Eng J Med1991，324，： | 1 |
| 4 | Homozygously deleted gene DACHI regulates tumor-initiating activity of gliomacells显示文摘 | Watanabe A Ogiwara H Ehata S | 2011 | Proc Natl Acad Sci U S A2011，108，12： | 1 |
| 5 | Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-β显示文摘 | Katsuno Y Ehata S Yashiro M | 2012 | J Pathol2012，228，3： | 1 |
| 6 | Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis 显示文摘 | Omata M Ehata T Yokosuka O | 1991 | N Engl J Med1991，324，24： | 1 |
| 7 | Variations in codons 84-101 in core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection 显示文摘 | Ehata T Omato M Yokosuka O | 1992 | J Clin Invest1992，89，： | 1 |
| 8 | The two different states of hepatitis B virus DNA in asymptomatic carriers:HBeantigen-positive versus anti-HBe-positive asymptomastic carriers显示文摘 | Yokosuka O ehata T | 1998 | Dig Dis Sci1998，43，： | 1 |
| 9 | Concentration missense mutations is core gene of hepatitis B virus显示文摘 | Chuang WL Omata M Ehata T | 1993 | Dis Sci1993，38，： | 1 |
| 10 | Mutations in the preeore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis 显示文摘 | Omata M T Ehata O Yokosuka | 1991 | N Engl J Med1991，324，： | 1 |
| 11 | Propofol injection pain is not alleviated by pretreatment with flurbiprofen axetil, a prodrug of a nonsteroidal antiinflammatory drug 显示文摘 | KARASAWA F EHATA T OKUDA T | 2000 | J Anesth2000，14，3： | 1 |
| 12 | Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis显示文摘 | OMATA M EHATA T YOKOSUKA O | 1991 | N Engl J Med1991，324，24： | 1 |
| 13 | Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis显示文摘 | Omata M Ehata T Yokosuka O | 1991 | N Engl J Med1991，324，24： | 1 |
| 14 | Tumor-promoting functions of transforming growth factor-β in progression of cancer显示文摘 | Miyazono K Ehata S Koinuma D | 2012 | Ups J Med Sci2012，117，2： | 1 |
| 15 | Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis显示文摘 | Omata M Ehata T Yokosuka O | 1991 | N Engl J Med1991，324，24： | 1 |
| 16 | Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC ( A ) cells 显示文摘 | Azuma H Ehata S Miyazaki H | 2005 | Journal of the National Cancer Institute2005，97，23： | 1 |
| 17 | Bone morphogenetic protein-2 and-4 play tumor suppressive roles in human diffuse-type gastric carcinoma显示文摘 | Shirai YT Ehata S Yashiro M | 2011 | Am J Pathol2011，179，6： | 1 |
| 18 | Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals显示文摘 | Nishimori H Ehata S Suzuki HI | 2012 | J Biol Chem2012，287，20： | 1 |
| 19 | Propofol injection pain is not alleviated by pretreatment with flurbiprofen axetil,a prodrug of a nonsteroidal antiinflammatory drug显示文摘 | Karasawa F Ehata T Okuda T Satoh T | | 0，，： | 1 |
| 20 | Ki26894,a novel transforming growth factor-beta type Ⅰ receptor kinase inhibitor,inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line显示文摘 | Ehata S Hanyu A Fujime M | 2007 | Cancer Science2007，98，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员